Skip to main content
Pure Biologics S.A. logo

Pure Biologics S.A. — Investor Relations & Filings

Ticker · PUR ISIN · PLPRBLG00010 LEI · 2594002TXS19AUYHIF82 WAR Manufacturing
Open in API
Filings indexed 515 across all filing types
Latest filing 2025-07-08 AGM Information
Country PL Poland
Listing WAR PUR

About Pure Biologics S.A.

https://purebiologics.com/

Pure Biologics S.A. is a biopharmaceutical company engaged in the discovery and development of novel biological drugs and non-systemic therapies. The company leverages its expertise in antibody and aptamer technologies to create innovative treatments. Its therapeutic portfolio is primarily focused on immuno-oncology. A key aspect of its strategy is the development of original, non-generic and non-biosimilar, biological drug candidates.

Recent filings

Filing Released Lang Actions
Treść uchwały nr 17 ZWZ z dnia 30 czerwca 2025 r.
AGM Information Classification · 98% confidence The document is titled "Uchwała nr 17/2025 Zwyczajnego Walnego Zgromadzenia..." (Resolution No. 17/2025 of the Annual General Meeting...). The content details resolutions regarding the increase of share capital, public offering of new shares, determination of the subscription right date, dematerialization, and applying for admission to trading on the regulated market (GPW). These actions are formal decisions made by the shareholders during a general meeting. Since the document explicitly details the resolutions passed at the Annual General Meeting (Zwyczajne Walne Zgromadzenie), it falls under the category of AGM Information.
2025-07-08 Polish
Korekta raportu bieżącego nr 23/2025 w sprawie treści uchwał podjętych przez Zwyczajne Walne Zgromadzenie Pure Biologics S.A. z dnia 30 czerwca 2025 r. - Content (PL)
AGM Information Classification · 95% confidence The document is a correction ('korektę') to a previous current report (raport bieżący) concerning resolutions passed at the Annual General Meeting (Zwyczajne Walne Zgromadzenie - ZWZ). The core subject is the correction of a typographical error ('omyłkę pisarską') regarding the series designation of new shares ('P' instead of 'P1') related to a capital increase and public offering, which was originally decided upon at the AGM. Since the document is a formal correction about resolutions passed at the AGM, and it explicitly mentions the AGM and its resolutions, it relates closely to AGM proceedings. However, the primary action described is the correction of a formal resolution regarding capital structure changes (share issuance/offering). The content strongly suggests a formal regulatory filing correcting prior information about a significant corporate action (capital increase/share issuance) that was approved at the AGM. Given the specific nature of correcting resolutions about capital structure changes (share issuance/offering), it fits best under Capital/Financing Update (CAP) or potentially AGM-R. Since the correction is about the mechanics of a share issuance approved at the AGM, CAP is a strong candidate, but the context is explicitly tied to the ZWZ resolutions. Because the document is a formal regulatory report correcting resolutions from the ZWZ, and the resolutions themselves concern capital changes, I will prioritize the nature of the correction. The document is a formal regulatory report correcting resolutions from the ZWZ. Since the correction pertains to the mechanics of a share issuance/capital increase, 'CAP' (Capital/Financing Update) is highly relevant. However, the document is explicitly titled as a correction to a report about the ZWZ resolutions. Given the options, 'AGM-R' covers materials related to the AGM, and this is a direct follow-up correction to AGM resolutions. Since the document is short and is a formal regulatory filing correcting prior information, 'RPA' (Report Publication Announcement) is a possibility if it were just announcing the correction, but this text *is* the correction content. I will classify it as AGM-R because the entire context revolves around correcting the official record of the Annual General Meeting resolutions.
2025-07-08 Polish
Lista Akcjonariuszy posiadających co najmniej 5% głosów na Zwyczajnym Walnym Zgromadzeniu Pure Biologics S.A. 30 czerwca 2025 r. - Content (PL)
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states that the Issuer ("Emitent") is publicly disclosing a list of shareholders holding at least 5% of the votes at the Annual General Meeting ("Zwyczajnym Walnym Zgromadzeniu Spółki" or "ZWZ") held on June 30, 2025. It then lists the shareholders, their share counts, and their corresponding voting percentages at the meeting and in the company overall. This content directly relates to the official results of shareholder voting at a general meeting. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA). The document is short and contains the results directly, not just an announcement of results.
2025-06-30 Polish
Treść uchwał podjętych przez ZWZ Spółki w dniu 30 czerwca 2025 r.
AGM Information Classification · 100% confidence The document text is titled 'Uchwała Nr 1/2025 Zwyczajnego Walnego Zgromadzenia Pure Biologics Spółka Akcyjna z siedzibą we Wrocławiu z dnia 30 czerwca 2025 roku' (Resolution No. 1/2025 of the Annual General Meeting of Pure Biologics S.A. dated June 30, 2025). The content consists of multiple numbered resolutions passed during this meeting, covering topics like electing the chairman, approving the agenda, approving the management report, the supervisory board report, and the financial statements for the year 2024. The key phrase is 'Zwyczajne Walne Zgromadzenie' (Annual General Meeting or AGM). This directly corresponds to the AGM Information category.
2025-06-30 Polish
Treść uchwał podjętych przez Zwyczajne Walne Zgromadzenie Pure Biologics S.A. 30 czerwca 2025 r. - Content (PL)
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document text explicitly states that the Management Board ('Zarząd') is enclosing the content of the resolutions ('treść uchwał') adopted by the Annual General Meeting ('Zwyczajne Walne Zgromadzenie Emitenta' or 'ZWZ') held on June 30, 2025. It details the voting results (votes for, against, abstained) for these resolutions. This content directly relates to the official results from a shareholder meeting, which aligns perfectly with the definition of 'Declaration of Voting Results & Voting Rights Announcements'.
2025-06-30 Polish
Rozpoczęcie negocjacji z ACRX Investments - Content (PL)
Capital/Financing Update Classification · 99% confidence The document text describes the execution of a letter of intent (list intencyjny) between the Company (Spółka) and an Investor (ACRX Investments Limited) regarding the extension of a loan repayment deadline and the potential subscription for a new share issuance up to PLN 4,000,000 if existing shareholders do not exercise their pre-emptive rights. This clearly relates to financing activities, capital structure changes, and potential share issuance. 1. It is not an AGM-R, 10-K, AR, MANG, CT, DVA, DLST, DIRS, ER, SR, FS, CGR, IRAT, IR, IP, LTR, NAV, DIV, PSI, DEF 14A, or POS. 2. It is not a simple announcement of a report (RPA/RNS) as it contains substantive details about a transaction/agreement. 3. It directly concerns a loan (financing) and a potential new share issue (capital structure change). 4. Comparing the definitions, 'Capital/Financing Update (Code: CAP)' is the most appropriate fit, as it covers fundraising, financing activities, and capital structure changes. 5. The document length (1148 chars) is short, but the content is substantive negotiation/agreement detail, not just a placeholder announcement.
2025-06-30 Polish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.